PIM1 and acute myeloid leukemia: In this study, we utilized a newly developed, small molecule pan‐PIM inhibitor, SEL24‐B489, which previously showed favourable toxicity profile and encouraging results in preclinical AML models.25 SEL24‐B489 is currently under clinical development in a phase I/II trial in AML patients (clinicaltrials.gov: NCT03008187).